Clinical Trial: Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT06953882) titled 'Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy' on April 01.

Brief Summary: The proposed study holds substantial clinical significance, with the potential to revolutionize the treatment of moderate to high-anatomical risk, low-genomic risk, ER-positive, HER2-negative breast cancer. The investigators hypothesize that patients are less likely to discontinue the CDK4/6 inhibitor in 1 year when it is given without adjuvant chemotherapy. If successful, this research could lead to a paradigm shift in breast cancer management, improving patient outcomes...